Development of Oligonucleotide-Based miR-132 Antagonists for the Treatment of NASH. Development of Oligonucleotide-Based miR-132 Antagonists for the Treatment of NASH Post navigation Previous: Discovery of Anti-miR-17 Oligonucleotide RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney DiseaseNext: Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease
